Revolutionizing IBD Treatment: The Promise of Infliximab Biosimilar Dose Escalation
Exploring Enhanced Clinical Response in Ulcerative Colitis and Crohn's Disease through CT-P13 Therapy
Topline:
A recent study has unveiled that escalating the dose of the infliximab biosimilar CT-P13 significantly enhances clinical response and remission rates in inflammatory bowel disease (IBD) patients who initially lost response to induction therapy, marking a significant stride in personalized IBD management without raising safety concerns.
Study Details:
Keep reading with a 7-day free trial
Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.